View Document Preview and Link Document Date: 2015-05-06 06:45:36 Open Document File Size: 444,87 KB Share Result on Facebook
City Washington / D.C. / Lexington / / Company Goldman Sachs & Co. / Sullivan & Cromwell LLP / Galaxy Merger Sub Inc. / Alexion Pharmaceuticals Inc. / Lazard / J.P. Morgan / Bank of America Merrill Lynch / Ropes & Gray LLP / Baker Brothers Investments / Synageva BioPharma Corp. / / Continent Europe / / Country France / Japan / United States / / Currency USD / / Event General or Shareholder Meeting / FDA Phase / M&A / Product Issues / Business Partnership / Reorganization / Security Buyback / Funding / Conference Call / / Facility Combined pipeline / Acquisition Creates Most Robust Rare Disease Pipeline / Expands Manufacturing Capabilities Synageva’s pipeline / Preclinical pipeline / / IndustryTerm document-retrieval services / pharmaceutical industry / manufacturing platform / Rare Disease Treatment / manufacturing / Therapies for Patients with Devastating and Rare Diseases / biotechnology product candidates / biotechnology / manufacturing technology / biopharmaceutical industry / manufacturing capabilities / treatment for patients with atypical hemolytic uremic syndrome / biopharmaceutical / therapeutic products / / MedicalCondition hypophosphatasia / ultra-rare disorders / Rare Diseases / atypical hemolytic uremic syndrome / genetic and progressive rare metabolic disease / mucopolysaccharidosis IIIB / Hunter syndrome / genetic disorder / Fabry disease / diseases / disorders / ultra-rare and life-threatening blood disorder / paroxysmal nocturnal hemoglobinuria / blood clots / hemolytic uremic syndrome / LAL Deficiency / additional severe and rare disorders / Pompe disease / chronic uncontrolled complement activation / metabolic rare disease / severe and rare disorders / rare disease / ultra-rare and life-threatening disorders / robust rare disease / / MedicalTreatment enzyme replacement therapy / / Organization European Union / Securities and Exchange Commission / Ministry of Health / Synageva’s mission / European Medicines Agency / U.S. Food and Drug Administration / / Person David Hallal / Leonard Bell / Sanj K. Patel / Felix Baker / / / Position financial advisor / Chief Executive Officer / board member and leader / legal counsel / financial advisors / President and Chief Executive Officer / Governor / Chairman / Hunter / Chairman of Board of Directors / / Product 50country operating platform / Soliris / Authorization Application / Kanuma / SBC-103 / metabolic process / Strensiq / 50country / Priority Review / / Technology drug discovery / biotechnology / / URL http / SocialTag 
Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi